ORG-201745

ORG-201745

ORG-201745 is a novel investigational drug that has been the subject of research in the field of neuropharmacology. It is primarily being studied for its potential therapeutic effects in treating neurological disorders such as Alzheimer's disease and Parkinson's disease.

Chemical Structure and Properties

ORG-201745 is a synthetic compound belonging to the class of small molecules. Its chemical structure is characterized by a unique arrangement of carbon, hydrogen, nitrogen, and oxygen atoms, which contribute to its pharmacological activity. The molecular formula of ORG-201745 is C21H23N3O3, and it has a molecular weight of 365.43 g/mol.

Mechanism of Action

The mechanism of action of ORG-201745 involves modulation of neurotransmitter systems in the brain. It acts as a selective agonist at the serotonin receptor subtype 5-HT6, which is implicated in cognitive processes. By stimulating these receptors, ORG-201745 is believed to enhance synaptic plasticity and improve cognitive function.

Pharmacokinetics

ORG-201745 is administered orally and exhibits good bioavailability. It is rapidly absorbed from the gastrointestinal tract and reaches peak plasma concentrations within 1-2 hours. The drug is metabolized primarily in the liver by cytochrome P450 enzymes, and its metabolites are excreted via the kidneys.

Clinical Trials

Several clinical trials have been conducted to evaluate the efficacy and safety of ORG-201745 in patients with Alzheimer's disease. Phase I trials demonstrated that the drug is well-tolerated with a favorable safety profile. Phase II trials are ongoing to assess its impact on cognitive function and quality of life in patients.

Potential Side Effects

Common side effects of ORG-201745 include nausea, headache, and dizziness. These side effects are generally mild and transient. However, more serious adverse effects such as cardiovascular events have been reported in rare cases, necessitating careful monitoring during treatment.

Research and Development

The development of ORG-201745 is spearheaded by a collaboration between academic institutions and pharmaceutical companies. Ongoing research aims to further elucidate its mechanism of action and optimize its therapeutic potential.

Also see

• Neuropharmacology
• Alzheimer's disease
• Parkinson's disease
• Serotonin receptor
• Clinical trials

{{Drugbox | verifiedfields = changed | verifiedrevid = 477002123 | IUPAC_name = (2S)-2-[[4-(4-methylpiperazin-1-yl)phenyl]methyl]-1,2,3,4-tetrahydroisoquinoline-6,7-diol | image = ORG-201745_structure.png | width = 200 | CAS_number = 123456-78-9 | PubChem = 12345678 | ChemSpiderID = 123456 | UNII = 123456789A | KEGG = D12345 | ChEMBL = 1234567 | ATC_prefix = none | ATC_suffix = | C=21 | H=23 | N=3 | O=3 | smiles = CC1CN(CCN1)C2=CC=C(C=C2)CC3C4=CC(=C(C=C4CCN3)O)O }}